Tag: Malaria
-
MK-7602: A First-in-Class Antimalarial Candidate Aiming to Beat Resistance and Cut Transmission
New Hope in the Fight Against Malaria: Introducing MK-7602 Researchers have unveiled a new antimalarial drug candidate, MK-7602, described as a first-in-class clinical candidate designed to tackle two of the most pressing challenges in malaria control: rising drug resistance and ongoing transmission. While still early in development, the compound represents a potential shift in how…
-
New Antimalarial Candidate MK-7602 Shows Promise Against Resistance and Transmission
Breakthrough Candidate in the Fight Against Malaria A new antimalarial drug candidate, MK-7602, is showing early promise in addressing two of the most pressing challenges in malaria control: rising drug resistance and ongoing transmission. Developed as a first-in-class clinical candidate, MK-7602 represents a strategic advance in the global effort to reduce malaria morbidity and move…
-
New Antimalarial Candidate MK-7602 Aims to Beat Resistance and Cut Transmission
Overview of MK-7602 and Why It Matters Researchers have unveiled a first-in-class antimalarial candidate, MK-7602, designed to confront the growing problem of drug resistance and potentially reduce malaria transmission. The program represents a strategic pivot in the field, aiming to deliver a drug with a unique mechanism of action that can stay effective as parasites…
-
How Asia-like Artemisinin Resistance Is Emerging in Africa
Understanding the question: What is artemisinin resistance? Artemisinin-based combination therapies (ACTs) are the frontline treatment for uncomplicated malaria caused by Plasmodium falciparum. In parts of Asia, resistance to artemisinin arose when the parasite evolved mutations in the kelch13 (K13) gene, slowing parasite clearance after drug exposure. Over time, resistance also spread to partner drugs, complicating…
-
Global Fund Donations Shortfall Threatens HIV, TB and Malaria Fight
Overview: A Funding Gap That Has Everyone on Edge The fight against HIV, tuberculosis (TB), and malaria—three of the world’s deadliest infectious diseases—faces an alarming funding gap. Advocates warn that a shortfall in donations to the Global Fund to Fight Aids, Tuberculosis and Malaria could destabilize essential programs, slow progress, and undermine the hard-won gains…
-
Global Health Fund Shortfall Threatens HIV, TB, and Malaria Control
Overview: A critical funding gap for HIV, TB, and malaria programs The fight against three of the world’s deadliest infectious diseases—HIV, tuberculosis (TB), and malaria—faces a fragile footing as funding to the Global Fund to Fight AIDS, Tuberculosis and Malaria falls short. Advocates warn that the vital programs designed to prevent new infections, supply lifesaving…
-
Global Fund Donations Risk HIV, TB and Malaria Fight
Overview: A fragile funding moment for a global health cornerstone The Global Fund to Fight AIDS, Tuberculosis and Malaria plays a pivotal role in the world’s response to three of the deadliest infectious diseases. With the latest round of donor contributions falling short of the required $18 billion target, advocates warn that momentum could stall,…
-
WHO Approves First Child-Friendly Primaquine to Treat Malaria Relapse
Overview: A historic step in pediatric malaria care The World Health Organization has approved the first-ever child-friendly primaquine tablets for treating malaria relapse in children, marking a significant milestone in the global fight against malaria. This development, backed by collaboration between Medicines for Malaria Venture (MMV) and Fosun Pharma with funding and strategic support from…
-
WHO Approves First Child-Friendly Primaquine Tablets to Fight Malaria Relapses
Groundbreaking approval for pediatric malaria treatment The World Health Organization (WHO) has approved the first-ever child-friendly primaquine tablets designed to treat relapse-causing malaria in children. This milestone, made possible through collaboration between Medicines for Malaria Venture (MMV), Fosun Pharma, and support from Unitaid, marks a significant step toward safer, more effective malaria elimination strategies for…
-
WHO Approves First Child-Friendly Paediatric Primaquine to Tackle Malaria Relapse
Global milestone in malaria elimination The World Health Organization (WHO) has approved the first-ever child-friendly paediatric primaquine tablets, marking a significant advance in the fight against malaria relapse in children. This development promises safer, easier dosing for young patients and strengthens malaria elimination strategies in endemic regions. What makes the new tablets different? Traditionally, primaquine…